|
Trade Wars
Tax Reforms, Falling Interest Rates Boost 2026 M&A Outlook: KPMG
Two-thirds of U.S. business leaders plan to do more merger-and-acquisition deals in 2026 compared with this year, according to survey results released Wednesday by Big Four accounting and consulting firm KPMG. Dealmakers responding to the survey pointed to the expectation of further interest-rate cuts next year as a key driver of future M&A activity, coupled with tax policy changes under the One Big Beautiful Bill Act, according to the report.
“After the false dawns of the last two years, the tailwinds of falling interest rates and lower taxes are expected to overcome the headwinds of tariffs and the [government] shutdown to bring a much better year for M&A,” Dean Bell, head of deal advisory and strategy for KPMG US, said in a statement included in the report. “Lowering the cost of capital increases the affordability of leveraged transactions, providing dealmakers with enhanced flexibility and confidence to pursue new opportunities,” Mitch Berlin, Ernst & Young Americas vice chair at EY-Parthenon said in an email last week.
Read more at Manufacturing Dive
Airbus Delivers 10 A321neos In 1 Day In Push To Meet End-Of-Year Delivery Target
Airbus is pushing hard as the year 2025 comes to an end. The European plan maker ended November with 72 deliveries, totaling $657 for the year. In order to achieve its goal of 820 aircraft deliveries this year, it left a final balance of 133 to go. With such an ambitious goal, the drive to maximize output is reaching its climax, which led to December 19th, when a total of 10 A321neos were handed off to customers in one day.
The December 19th surge comes as the manufacturer faces a steep challenge to meet its revised 2025 goal of 790 aircraft by the end of the year. Only a day before, on December 18, Airbus celebrated the delivery of its 800th aircraft assembled at its Tianjin, China facility—an A321neo handed over to Air China. Deliveries originated from all the major final assembly lines in Hamburg (XFW), Tianjin (TSN), and Toulouse (TLS), but none from the US plant in Mobile, Alabama. Reuters reported that the manufacturer in November discovered panel defects with its A320 suppliers, which slowed down assembly line progress. According to Reuters, this also led to some customers being reluctant to take delivery until they were confident that the issue was resolved or there was a satisfactory plan in place to remedy the issue.
Read more at Simple Flying
AI In The Car: Bosch Presents Cockpit Innovations At CES 2026
The automotive industry is undergoing a fundamental transformation, with software – and especially artificial intelligence (AI) – becoming a core component of the future driving and in-cabin experience. Bosch sees a significant and growing market for such AI cockpits. Various market research institutes, including Grand View Research* and MarketsandMarkets*, predict that the market for AI-enabled in-vehicle infotainment (IVI) solutions will reach a volume of approximately 17 billion euros by 2030. The company expects sales of over 2 billion euros with such IVI solutions by the end of the decade and strives for a leading position among the top three providers.
A key application of this is turning unproductive downtime in the car into productive work time. Together with Microsoft, Bosch is transforming the car into a mobile office without compromising on driver safety. By integrating Microsoft Foundry and specialized features for the cockpit, the solution provides seamless access to the Microsoft 365 productivity suite. For example, a driver can use an intuitive voice command to join a Microsoft Teams call, which in turn prompts the system to proactively activate adaptive cruise control. This seamless, cross-domain interaction helps to create a journey that is both productive and safe – a significant value for commuters and frequent drivers. At its core, the platform leverages the powerful “NVIDIA DRIVE AGX Orin system-on-chip” (SoC), which forms the foundation for complex AI applications in the cockpit.
Read more at Bosch
Waymo Robotaxis Stop In The Streets During San Francisco Power Outage
A massive power outage in San Francisco over the weekend led Waymo self-driving taxis to stop working around the city. "Significant and extensive" damage from a fire in a substation caused the Saturday afternoon outage that left more than 100,000 customers without power, utility provider PG&E said in a statement. Videos posted to social media showed Waymo robotaxis halted in the middle of city streets and intersections with their hazard lights flashing, as traffic jams grew and drivers zigzagged around the stopped cars.
Waymo initially paused all service in the Bay Area following the outage, but has since resumed its operations, a spokesperson said in a statement. During the outage, many traffic signals stopped working, city officials said, and Mayor Daniel Lurie deployed police officers, fire crews, and others to help with the flow of cars on the roads. Some commuter train lines and stations shut down, as well.
Read more at BBC
Pill Version of Wegovy Is Approved for Use in the U.S.
U.S. regulators approved the first GLP-1 weight-loss pill—a tablet formulation of Novo Nordisk’s Ozempic and Wegovy—ushering in a new era of the obesity-drugs revolution that is expected to broaden their use. Novo Nordisk said Monday it plans to start selling the new pill in the U.S. in early January, with a cash price of $149 a month for the starting dose. The Food and Drug Administration approval is a milestone because weekly shots such as Wegovy and Eli Lilly’s Zepbound have dominated the anti-obesity market to date. The FDA also approved the Wegovy pill to reduce the risk of heart attacks and strokes in people with established cardiovascular disease, a use already approved for the Wegovy shot. Leerink Partners analyst David Risinger estimates that pills will eventually make up about 25% of the projected $150 billion total obesity-drug market.
Novo Nordisk’s new drug, which the company plans to call Wegovy pill, has the main ingredient semaglutide, which is the same ingredient in its injected diabetes drug Ozempic and weight-loss drug Wegovy. Novo Nordisk has been selling a pill formulation of semaglutide, Rybelsus, that is approved specifically for Type 2 diabetes and not weight loss. Semaglutide is a GLP-1 drug, which works by mimicking a gut hormone to reduce appetite, make people feel full sooner when eating and slow the rate of food leaving the stomach for the intestine.
Read more at The WSJ
Alphabet To Acquire Data Center And Energy Infrastructure Company Intersect
Google parent Alphabet on Monday announced it will acquire Intersect, a data center and energy infrastructure company, for $4.75 billion in cash in addition to the assumption of debt.Alphabet said Intersect’s operations will remain independent, but that the acquisition will help bring more data center and generation capacity online faster. “Intersect will help us expand capacity, operate more nimbly in building new power generation in lockstep with new data center load, and reimagine energy solutions to drive US innovation and leadership,” Sundar Pichai, CEO of Google and Alphabet, said in a statement.
Alphabet said Monday that Intersect will work closely with Google’s technical infrastructure team, including on the companies’ co-located power site and data center in Haskell County, Texas. Google previously announced a $40 billion investment in Texas through 2027, which includes new data center campuses in the state’s Haskell and Armstrong counties. Intersect’s operating and in-development assets in California and its existing operating assets in Texas are not part of the acquisition, Alphabet said.
Read more at CNBC
Samsung Biologics Pays GSK $280M To Secure First US Manufacturing Site
CDMO juggernaut Samsung Biologics is making manufacturing inroads in the U.S. by way of an acquisition. Samsung Bio’s U.S. subsidiary will pay $280 million to acquire GSK's Human Genome Sciences and its two pharmaceutical manufacturing plants at a campus in Rockville, Maryland. The site, which will mark Samsung Bio’s first for production in the U.S., features a total 60,000 liters of drug substance capacity and is equipped to handle clinical and commercial manufacturing from small to large scale, according to a Dec. 21 press release.
Samsung Bio says it will continue to manufacture products already being made at the site and noted that it plans to invest further to expand capacity and upgrade technology there “to further support a more resilient U.S. supply chain for critical biologic medicines.” Samsung Bio also plans to retain “more than 500” employees at the site. The Korean CDMO says that it expects the deal to close toward the end of 2026’s first quarter.
Read more at Fierce Pharma
Adoption Of Automation, AI-Powered Tools Accelerating Across Sectors, Survey Shows
A survey of 400 U.S. companies revealed key insights on a drive towards physical automation equipment such as robotics and other AI-powered automation tools, showing that companies across sectors are either already using this technology or are planning to do so. The findings come from the German modular robotics company RobCo and its Automation Readiness Index, a survey of 400 U.S. business leaders in sectors including manufacturing, construction, engineering and health care, conducted to address how warehouses and factories are paying for automation, and what’s blocking the next wave of robots in those sectors.
According to survey findings, nearly 95% of U.S. industrial businesses plan to introduce new automation within the next three years, signaling a major shift in how American industry operates, according to RobCo. The survey showed that automation is already well underway, with 47% of respondents already using some form of AI-powered automation, and 94% having at least partly integrated their physical and digital systems, connecting factory machines to computers for tasks like monitoring production. According to the research, this trend is likely to accelerate, with 76% of companies saying they’re very likely to introduce new automation in the next three years. Among companies already using automation, over half reported increased productivity, time savings, reduced waste and improved resource efficiency.
Read more at Smart Industry
|